HMGB-1 as a potential target for the treatment of diabetic retinopathy

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 3062-3067

  Zhao, Hailan ^a   Zhang, Jingzhuang ^a   Yu, Jie ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Diabetic retinopathy; Retinal ganglion cells; Toll like receptor 4

Indexed keywords

GLUCOSE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 4; GLUCOSE BLOOD LEVEL; HMGB1 PROTEIN, HUMAN; NFKB1 PROTEIN, HUMAN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TLR4 PROTEIN, HUMAN;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; INTRACELLULAR SIGNALING; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; RETINA GANGLION CELL; SURVIVAL RATE; WESTERN BLOTTING; ANALYSIS; BLOOD; CELL LINE; CELL SURVIVAL; CHEMISTRY; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; METABOLISM; PERIPHERAL NEUROPATHY; UPREGULATION;

BLOOD GLUCOSE; CELL LINE; CELL SURVIVAL; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HMGB1 PROTEIN; HUMANS; INFLAMMATION; NF-KAPPA B P50 SUBUNIT; PERIPHERAL NERVOUS SYSTEM DISEASES; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL GANGLION CELLS; RNA, MESSENGER; RNA, SMALL INTERFERING; TETRAZOLIUM SALTS; THIAZOLES; TOLL-LIKE RECEPTOR 4; TRANSFECTION; UP-REGULATION;

EID: 84944450238     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.894453     Document Type: Article

References (22)

1. Antonetti DA, Klein R, Gardner TW: Diabetic retinopathy. N Engl J Med, 2012; 366: 1227–39
2. Mysona BA, Matragoon S, Stephens M et al: Imbalance of the nerve growth factor and its precursor as a potential biomarker for diabetic retinopathy. Biomed Res Int, 2015; 2015: 571456
3. Wang Y, Yuan Y, Jiang H: Serum and vitreous levels of visfatin in patients with diabetic retinopathy. Med Sci Monit, 2014; 20: 2729–32
4. Boynton GE, Stem MS, Kwark L et al: Multimodal characterization of proliferative diabetic retinopathy reveals alterations in outer retinal function and structure. Ophthalmology, 2015; 122: 957–67
5. Hao M, Li Y, Lin W et al: Estrogen prevents high-glucose-induced damage of retinal ganglion cells via mitochondrial pathway. Graefes Arch Clin Exp Ophthalmol, 2015; 253: 83–90
6. Jia WC, Liu G, Zhang CD, Zhang SP: Formononetin attenuates hydrogen peroxide (H2O2)-induced apoptosis and NF-kappaB activation in RGC-5 cells. Eur Rev Med Pharmacol Sci, 2014; 18: 2191–97
7. Kim SJ, Yoo WS, Choi M et al: Increased O-GlcNAcylation of NF-kappaB enhances retinal ganglion cell death in Streptozotocin-induced diabetic retinopathy. Curr Eye Res, 2015: 1–9
8. Isshiki T, Sakamoto S, Kinoshita A et al: Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respiration, 2015; 89: 201–7
9. Sugimoto K, Ohkawara H, Nakamura Y et al: Receptor for advanced glycation end products - membrane type1 matrix metalloproteinase axis regulates tissue factor expression via RhoA and Rac1 activation in high-mobility group box-1 stimulated endothelial cells. PLoS One, 2014; 9: e114429
10. Kim HY, Park SY, Lee SW et al: Inhibition of HMGB1-induced angiogenesis by cilostazol via SIRT1 activation in synovial fibroblasts from rheumatoid arthritis. PLoS One, 2014; 9: e104743
11. Nogueira-Machado JA, de Oliveira Volpe CM: HMGB-1 as a target for inflammation controlling. Recent Pat Endocr Metab Immune Drug Discov, 2012; 6: 201–9
12. Gong Y, Jin X, Wang QS et al: The involvement of high mobility group 1 cytokine and phospholipases A2 in diabetic retinopathy. Lipids Health Dis, 2014; 13: 156
13. Tao X, Wan X, Xu Y et al: Dioscin attenuates hepatic ischemia-reperfusion injury in rats through inhibition of oxidative-nitrative stress, inflammation and apoptosis. Transplantation, 2014; 98: 604–11
14. Jialal I, Rajamani U, Adams-Huet B, Kaur H: Circulating pathogen-associated molecular pattern – binding proteins and High Mobility Group Box protein 1 in nascent metabolic syndrome: implications for cellular Toll-like receptor activity. Atherosclerosis, 2014; 236: 182–87
15. Nawaz MI, Abouammoh M, Khan HA et al: Novel drugs and their targets in the potential treatment of diabetic retinopathy. Med Sci Monit, 2013; 19: 300–8
16. Price LD, Au S, Chong NV: Optomap ultrawide field imaging identifies additional retinal abnormalities in patients with diabetic retinopathy. Clin Ophthalmol, 2015; 9: 527–31
17. Furukawa MT, Sakamoto H, Inoue K: Interaction and colocalization of HERMES/RBPMS with NonO, PSF, and G3BP1 in neuronal cytoplasmic RNP granules in mouse retinal line cells. Genes Cells, 2015; 20: 257–66
18. Karuppagounder V, Arumugam S, Thandavarayan RA et al: Modulation of HMGB1 translocation and RAGE/NFkappaB cascade by quercetin treatment mitigates atopic dermatitis in NC/Nga transgenic mice. Exp Dermatol, 2015; 24(6): 418–23
19. Karuppagounder V, Arumugam S, Thandavarayan RA et al: Resveratrol attenuates HMGB1 signaling and inflammation in house dust mite-induced atopic dermatitis in mice. Int Immunopharmacol, 2014; 23: 617–23
20. Mohammad G, Siddiquei MM, Othman A et al: High-mobility group box- 1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Exp Eye Res, 2013; 107: 101–9
21. Shen X, Li WQ: High-mobility group box 1 protein and its role in severe acute pancreatitis. World J Gastroenterol, 2015; 21: 1424–35
22. Santos AR, Dvoriantchikova G, Li Y et al: Cellular mechanisms of high mobility group 1 (HMGB-1) protein action in the diabetic retinopathy. PLoS One, 2014; 9: e87574